A Phase II Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Eribulin (Primary) ; Sintilimab (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 08 Jun 2022 New trial record